0000899243-22-025476.txt : 20220706 0000899243-22-025476.hdr.sgml : 20220706 20220706181601 ACCESSION NUMBER: 0000899243-22-025476 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220701 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRAINGER DAVID J CENTRAL INDEX KEY: 0001887115 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40445 FILM NUMBER: 221070052 MAIL ADDRESS: STREET 1: C/O CENTESSA PHARMACEUTICALS PLC STREET 2: 3RD FL., 1 ASHLEY RD, ALTRINCHAM CITY: CHESHIRE STATE: X0 ZIP: WA14 2DT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc CENTRAL INDEX KEY: 0001847903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT BUSINESS PHONE: 44 7391 789784 MAIL ADDRESS: STREET 1: 3RD FLOOR STREET 2: 1 ASHLEY ROAD CITY: ALTRINCHAM, CHESHIRE STATE: X0 ZIP: WA14 2DT FORMER COMPANY: FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd DATE OF NAME CHANGE: 20210224 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-01 0 0001847903 Centessa Pharmaceuticals plc CNTA 0001887115 GRAINGER DAVID J C/O CENTESSA PHARMACEUTICALS PLC 3RD FL., 1 ASHLEY RD, ALTRINCHAM CHESHIRE X0 WA14 2DT UNITED KINGDOM 0 1 0 0 Chief Innovation Officer Ordinary Shares 2022-07-01 4 A 0 100000 0.00 A 913756 D Ordinary Shares 27500 I See footnote The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in 10 equal quarterly instalments with the first such quarterly vesting being on September 30, 2022. Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. /s/ Marella Thorell, attorney-in-fact 2022-07-06